67.05
-0.15 (-0.22%)
| Penutupan Terdahulu | 67.20 |
| Buka | 66.95 |
| Jumlah Dagangan | 829,500 |
| Purata Dagangan (3B) | 897,654 |
| Modal Pasaran | 36,441,329,664 |
| Harga / Pendapatan (P/E TTM) | 38.76 |
| Harga / Pendapatan (P/E Ke hadapan) | 63.29 |
| Harga / Jualan (P/S) | 5.29 |
| Harga / Buku (P/B) | 9.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2025 |
| Margin Keuntungan | 14.33% |
| Margin Operasi (TTM) | 14.05% |
| EPS Cair (TTM) | 1.65 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 57.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 121.06% |
| Nisbah Semasa (MRQ) | 0.500 |
| Aliran Tunai Operasi (OCF TTM) | 1.24 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 176.66 M |
| Pulangan Atas Aset (ROA TTM) | 5.28% |
| Pulangan Atas Ekuiti (ROE TTM) | 31.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | HENLIUS | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | 0.63 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HENLIUS | 36 B | - | 38.76 | 9.00 |
| BEONE MEDICINES | 296 B | - | 663.87 | 7.45 |
| INNOCARE | 23 B | - | - | 3.00 |
| ASCENTAGE-B | 17 B | - | - | 21.49 |
| KEYMED BIO-B | 17 B | - | - | 4.45 |
| EVEREST MED | 13 B | - | - | 2.92 |
|
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 51.34% |
| % Dimiliki oleh Institusi | 14.71% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |